Servier Việt Nam

Servier Việt Nam company information, Employees & Contact Information

We are committed to therapeutic progress to serve patient needs. Servier is present in Vietnam since 1993. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. We are a leader in cardiology, our ambition is to become a recognized and innovative player in oncology. The corporate growth is driven by our constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, cancer and diabetes, as well as by our activities in high-quality generic drugs. All Group employees are driven by shared Values and guided by a common Vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs. ------ Để báo cáo một tác dụng không mong muốn, một khiếu nại sản phẩm hoặc một câu hỏi y khoa liên quan đến sản phẩm của Servier, vui lòng liên hệ website https://servier.vn/contact-us/ To report an adverse event, a product complaint or a medical question regarding a Servier product, please contact the website https://servier.vn/contact-us/

Company Details

Employees
70
Address
138-142 Hai Ba Trung Street, 15th Floor,viet Nam
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
servier.vn
HQ
Da Kao Ward, Ho Chi Minh City
Looking for a particular Servier Việt Nam employee's phone or email?

Servier Việt Nam Questions

News

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - Servier

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier

Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease - Frontiers

Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease Frontiers

Integrated annual report 2023/2024 - Servier

Integrated annual report 2023/2024 Servier

Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Increased patient adherence thanks to health care professionals - Servier

Increased patient adherence thanks to health care professionals Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition - Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition Servier

Servier and Google Cloud Expand Partnership on using data and AI - Servier

Servier and Google Cloud Expand Partnership on using data and AI Servier

Servier tackles environmental challenges, transforming itself for a more sustainable future! - Servier

Servier tackles environmental challenges, transforming itself for a more sustainable future! Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 - Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 Servier

Learn more about our development portfolio - Servier

Learn more about our development portfolio Servier

See our bases throughout the world - Servier

See our bases throughout the world Servier

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences - Servier

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences Servier

Servier Executive Committee appointments - Servier

Servier Executive Committee appointments Servier

Our ambition for 2030 - Servier

Our ambition for 2030 Servier

The Group in figures - Servier

The Group in figures Servier

Our commitment to neurology - Servier

Our commitment to neurology Servier

7 start-ups hosted - Servier

7 start-ups hosted Servier

Servier x Owkin: AI-driven precision therapeutics - Servier

Servier x Owkin: AI-driven precision therapeutics Servier

Schema describing Servier’s governance structure - Servier

Schema describing Servier’s governance structure Servier

Our commitment to oncology - Servier

Our commitment to oncology Servier

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma - PR Newswire

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma PR Newswire

Servier is boosting its digital transformation with Google Cloud! - Servier

Servier is boosting its digital transformation with Google Cloud! Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN - Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN Servier

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US - Fierce Biotech

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US Fierce Biotech

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate - Fierce Biotech

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate Fierce Biotech

Servier reveals a new visual identity - Servier

Servier reveals a new visual identity Servier

The Research and Development Institute in Paris-Saclay - Servier

The Research and Development Institute in Paris-Saclay Servier

Fostering a healthy environment - Servier

Fostering a healthy environment Servier

PRISM BioLab, a new partner for Servier in immuno-oncology - Servier

PRISM BioLab, a new partner for Servier in immuno-oncology Servier

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect - Fierce Biotech

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect Fierce Biotech

Servier completes acquisition of Agios Pharmaceuticals’ oncology business - Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

Servier takes aim at US oncology market, doubling R&D lab space in Boston - Fierce Biotech

Servier takes aim at US oncology market, doubling R&D lab space in Boston Fierce Biotech

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M - Fierce Pharma

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M Fierce Pharma

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer - MedCity News

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer MedCity News

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says - Fierce Pharma

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

All our latest news - Servier

All our latest news Servier

Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' - Fierce Biotech

Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' Fierce Biotech

Tutorial Videos - Servier Medical Art

Tutorial Videos Servier Medical Art

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) - The New York Times

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) The New York Times

French drugmaker Servier ordered to pay $471m over Mediator scandal - RFI

French drugmaker Servier ordered to pay $471m over Mediator scandal RFI

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant